Here’s the Medical Care People Skip Because of Cost
According to a report from FamiliesUSA, an organization advocating for improved healthcare coverage, these are the medical services people forego when money gets tight:

We have experienced an impressive slowdown in the growth of healthcare expenditures in recent years, a slowdown attributed in part to the plethora of important drugs which have gone generic in recent years. But state Medicaid programs, according to a recent study in Health Affairs, could have slowed healthcare costs even more, if they had been quicker to switch patients from trade to…
With increasing frequency, Americans are purchasing health insurance plans that require high out-of-pocket costs. Chief among those costs are deductibles, the amount of money a person or family must spend out-of-pocket on medical care in a year before their health insurance “kicks in.” As this figure illustrates, from the Kaiser Family Foundation, deductibles have been…
Here is another great picture from the people at Vox. It shows the United States in the middle of OECD countries, when it comes to spending on social services, like healthcare, unemployment, and the like. Despite being in the middle, however, the US is better understood as an outlier, on two extremes of this spectrum….
There are many reasons that life expectancy is not a good measure of a health care system. For starters, how long people live is often more a function of public health systems then of medical care systems, with clean water and low rates of infectious diseases having more impact on people’s life expectancy than their…
Here is a video illustrating my take on why so many people still believe Obamacare includes a death panel, and why I think this kind of misguided believing is not a Republican thing, nor a Democratic thing, but…a HUMAN thing.
In a previous post, I argued in favor of Rob Califf as FDA Commissioner. Here is an article from the Duke Chronicle, exploring more of this important debate. Dr. Robert Califf, former vice chancellor of clinical and translational research, may soon be taking helm of the U.S. Food and Drug Administration, but not without resistance from organizations…